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ENGLISH SUMMARY 
Postoperative new onset atrial fibrillation (POAF) is a common complication 
following cardiac surgery and may develop in 10-65% of patients depending on the 
POAF definition, type of surgery and diagnostic method. Because POAF is associated 
with an increased risk of early and late mortality and morbidity, including stroke, 
POAF prevention is a focus in many centers. Medical prophylaxis is most frequently 
used to prevent POAF. However, medical prophylaxis for all patients may expose too 
many of them to potential adverse effects, and prophylactic treatment for all patients 
may not be cost-effective. Therefore, efforts to identify patients at an increased risk 
for POAF would be beneficial to take precautionary measures specifically in these 
high-risk patients to potentially decrease morbidity and mortality related to POAF. 
Therefore, a continuous awareness regarding possibilities to predict POAF is 
important. 
The cause of POAF is multifactorial, and therefore, multidirectional efforts are needed 
for doctors to be able to identify more high-risk patients. The overall aim of this PhD 
thesis is to serve as an example of a multidirectional search for potentially new 
predictors of POAF by performing three individual studies.  
Objectives and hypotheses: 
1.  To investigate whether ECG markers from routine pre-operative ECGs can be 
used in combination with clinical data to predict new-onset POAF following 
cardiac surgery. Hypothesis: Minor preoperative ECG changes can be used in 
combination with clinical data as predictors for the development of POAF in 
cardiac surgery.  
2. The primary aim was to evaluate whether the storage time of transfused RBC is 
associated with the development of POAF in patients undergoing cardiac surgery. 
Furthermore, we aimed to investigate whether RBC transfusion in general is 
associated with an increased risk of POAF. Hypothesis: RBC transfusion in 
general and increased storage time of transfused RBC is associated with an 
increased risk of POAF.  
3.  To evaluate whether concentrations of n-3 PUFA in atrial tissue and in the blood 
(plasma phospholipids) are associated with the development of POAF and whether 
concentrations in the atrial wall are reflected by concentrations in the blood. 
Hypothesis: Specific compositions of n-3 PUFA in atrial tissue are predictors of 
POAF and are reflected by the fatty acid composition in the blood.  
 
POSTOPERATIVE NEW-ONSET ATRIAL FIBRILLATION FOLLOWING CARDIAC SURGERY WITH SPECIAL 
REFERENCE TO POTENTIAL NEW PREDICTORS 
6 
Methods: 
Different study designs were used for the three individual studies included in this 
thesis. Study I was a retrospective case control study, while Study II was a 
retrospective observational cohort study based on prospectively collected data from 
different databases. In contrast, Study III was a prospective observational study that 
combined laboratory and clinical data.  
In Study I, demographic and clinical data regarding 100 adult patients (50 POAF, 50 
without POAF) who underwent coronary artery bypass grafting (CABG), valve 
surgery or combinations in Aalborg University Hospital between January 1, 2011 and 
December 31, 2014 were retrieved from the Western Denmark Heart Registry 
(WDHR) and patient records. Furthermore, paper tracings of pre-operative ECGs 
were collected and digitalized to perform automatic readings of specific ECG 
variables associated with left atrial enlargement and fibrosis. Patients with a pre-
operative history of AF, left or right incomplete/complete bundle branch block and 
patients with permanent pacemakers were excluded.   
In study II, pre-, per- and postoperative data were retrieved from the WDHR and local 
blood banks for patients who underwent CABG, valve surgery or combined 
procedures in Aalborg or Aarhus University Hospital between January 1, 2010 and 
December 31, 2014. Logistic regression was used to determine the risk of POAF 
according to the transfusion of RBCs on the day of surgery. Furthermore, we 
determined the trend in storage time of RBCs according to the risk of POAF using 
restricted cubic splines. Patients with a history of preoperative atrial fibrillation (AF), 
pacemakers and patients who received transfusions preoperative or beyond the day of 
surgery were excluded. 
In study III, a total of 50 patients undergoing first-time cardiac surgery between 
December 1, 2014 and April 30, 2015 at Aalborg University Hospital were enrolled. 
Venous blood and a tissue sample from the right atrial appendage were obtained 
perioperative. Clinical data and demographics for the patients were retrieved from the 
WDHR and patient records. Patients with a known history of AF and use of a 
pacemaker were excluded. Using gas chromatography, we assessed the content of 
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic 
acid (DHA) in the atrial tissue and in plasma phospholipids, and the measurements 
from tissue and blood were correlated with each other as well as with the development 
of POAF.  
Results: 
Study I: A subset of four pre-specified clinical variables (age, gender, body mass 
index, and type of surgery) were selected together with five ECG variables (QRS 
duration, PR interval, P-wave duration, signs of LA enlargement, and left ventricular 
7 
hypertrophy) were used in a multivariate ECG model to predict POAF. The addition 
of ECG variables to the specific clinical data significantly improved the area under 
the receiver operating characteristic curve from 0.54 to 0.67. Only 20% of patients 
with any one risk factors developed POAF, whereas 100% of the patients with four 
risk factors developed POAF. 
Study II: A total of 4,766 patients underwent surgery during the study period, and 
2,978 patients with a mean age of 66.4 years were included. Among these, 609 patients 
(21%) received ≥ 1 RBC transfusion on the day of surgery. POAF developed in 752 
patients (25%), and transfused patients were at an increased risk compared with non-
transfused patients (adjusted OR for patients receiving RBC: 1.37; 95% CI: 1.11-1.69, 
p=0.004). Although RBC transfusion was generally associated with the development 
of POAF, spline analyses did not reveal any systematic patterns to support an 
increased risk of POAF in patients receiving RBC with increasing storage time. 
Study III: One patient was excluded from the study due to an insufficient amount of 
atrial tissue for analysis. Twenty-two, 14, 10 and three patients underwent isolated 
CABG, valve or combined or other cardiac surgery, respectively. The mean ± SD age 
was 65.98 ±10.40 years. Eighteen patients (36.7%) developed POAF. Concentrations 
of EPA, DPA and DHA in the atrial wall or in plasma phospholipids did not predict 
the development of POAF, but there were significant correlations between the levels 
in atrial tissue and in plasma. 
Conclusion: 
ECG markers obtained from routine pre-operative ECG may be helpful in 
combination with specific clinical data in predicting new-onset POAF in patients 
undergoing cardiac surgery (Study I). Furthermore, RBC transfusion is also associated 
with an increased risk of POAF (Study II). However, the storage time of transfused 
allogeneic RBCs (Study II) and the levels of EPA, DPA and DHA in the atrial wall 
did not predict the development of POAF (Study III). Plasma phospholipid 
concentrations of n-3 PUFAs correlated significantly with concentrations in the atrial 
wall (Study III). 
The results of the individual studies included in this thesis represent a multidirectional 
search for potential new predictors associated with the development of POAF in 
patients undergoing cardiac surgery. The results from study I in particular may be 
helpful for the development of future predictions models regarding the risk of new-
onset POAF. 
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DANSK RESUME 
Postoperativ nyopstået atrieflimmer (POAF) er en almindelig komplikation til 
hjertekirurgi, og POAF ses typisk hos 10-65% af patienterne afhængig af hvordan 
POAF defineres, hvilken operation der gennemføres og metoden der benyttes med 
henblik på at stille diagnosen.  Da POAF er associeret med både tidlig og sen 
morbiditet inklusiv apopleksi samt mortalitet, er forebyggelse med henblik på at 
undgå POAF i fokus i mange centre. Medicinsk profylakse kan benyttes generelt, men 
dette vil potentielt udsætte for mange patienter for mulige bivirkninger, og en sådan 
profylakse er måske ikke omkostningseffektiv. Derfor kan forsøg på at identificere 
patienter der er i øget risiko for at udvikle POAF være gavnlige, idet særlige tiltag kan 
gøres i forhold til at reducere risikoen for POAF blandt disse høj-risiko patienter. Det 
er vigtigt at have en vedvarende opmærksomhed på muligheden for at forudsige 
udvikling af POAF. 
Årsagen til POAF er multifaktoriel og derfor er multidirektionale tiltag nødvendige 
hvis læger skal have muligheden for at identificere flere patienter der er i øget risiko 
for at udvikle POAF. Det overordnede formål med denne ph.d. afhandling er at give 
et eksempel på en multidirektional søgen efter potentielle nye prediktorer som er 
associeret med udvikling af POAF. Dette gøres ved at gennemføre tre individuelle 
undersøgelser.  
Formål: 
1. At undersøge om EKG markører identificeret i rutinemæssige præoperative 
EKG optagelser i kombination med kliniske data kan benyttes med henblik på at 
kunne forudsige om en patient vil udvikle POAF efter hjertekirurgi. Hypotese:  
Mindre præoperative EKG markører kan sammen med udvalgte data 
identificeres som værende prædiktorer for udvikling af POAF.  
2. At undersøge om den tid erytrocytter opbevares i blodbanken før transfusion er 
associeret med udvikling af POAF, og at undersøge om transfusion med 
erytrocytter generelt er associeret med POAF. Hypotese: Transfusion med røde 
blodlegemer og opbevaringstiden i blodbanken er associeret med en øget risiko 
for at udvikle POAF efter hjertekirurgi. 
3.  At undersøge om koncentrationen af marine n-3 flerumættede fedtsyrer (n-3 
PUFA) i atrievæv og i plasma fosfolipider er associeret med udvikling af POAF 
efter hjertekirurgi og om koncentrationen af n-3 PUFA i atrievævet afspejles af 
koncentrationen i blodet. Hypotese: Specifikke kompositioner af n-3 PUFA kan 
prædiktere POAF and kompositionen afspejler koncentrationen i blodet.  
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Metoder: 
Forskellige studie design er blevet i de tre individuelle studier som indgår i denne 
ph.d. afhandling. Study I var et retrospektivt Case-Kontrol studie medens Study II var 
et retrospektivt kohorte studie baseret på prospektivt indsamlede data. I modsætning 
hertil var Study III et prospektivt observationsstudie hvor kliniske og 
laboratoriemæssige data blev kombineret.  
In Studie I blev demografiske og kliniske data fra 100 voksne patienter (50 patienter 
med POAF og 50 uden POAF) som gennemgik koronar bypass kirurgi (CABG), 
klapkirurgi eller kombinationer heraf på enten Aalborg eller Aarhus 
universitetshospital i perioden 1. januar 2011 og 31. december 2014 indhentet fra 
Vestdansk Hjertedatabase (WDHR) og patientjournalerne. Endvidere blev 
præoperative EKG optagelser indsamlet og digitaliseret med henblik på automatisk 
aflæsning hvad angår specifikke EKG karakteristika som er associeret med forstørret 
venstre atrie eller fibrose i atrievæggen. Patienter med præoperativ AF venstre- eller 
højresidigt inkomplet/kompletgrenblok og patienter med permanente pacemakere 
blev ekskluderet.    
I studie II blev præ-, per- and postoperative data indsamlet fra WDHR og lokale 
blodbanker hvad angår patienter der havde gennemgået CABG, klapkirurgi eller en 
kombineret procedure på enten Aalborg or Aarhus Universitetshospital i perioden 1. 
januar 2010 og 31, december 2014. Logistisk regressions analyse blev anvendt med 
henblik på at bestemme risikoen for udvikling af POAF i relation til transfusion med 
erytrocytter på operationsdagen. Vi beregnede også betydningen af opbevarelsestiden 
i blodbanken før transfusion hvad angår risikoen for at udvikle POAF med spline 
analayser Patienter hos hvem præoperativ atrieflimmer indgik i annamnesen blev 
ekskluderet ligesom også patienter med pacemakere og patienter der modtog 
transfusion senere end i operationsdøgnet blev ekskluderet. 
I studie III blev 50 patients som skulle gennemgå en første-gangs CABG operation  
på Aalborg Universitetshospital inkluderet i perioden 1. december, 2014 og 30. april, 
2015. Peroperativt blev en venøs blodprøve og en biopsi fra højre atrie indsamlet. 
Kliniske data blev indsamlet fra WDHR og patientjournalerne. Patienter med 
præoperativ AF i anamnesen og pacemaker blev ekskluderet. Ved hjælp af gas 
kromatografi blev indholdet af eicosapentansyre acid (EPA), docosapentansyre acid 
(DPA) and docosahexaensyre (DHA)bestemt i atrievæv og i plasma fosfolipider og 
indholdet blev korreleret til udviklingen af POAF.  
Resultater: 
Studie I: Fire kliniske variable (alder, køn, body mass index, og operationstype) blev 
sammen med fem EKG variable (QRS duration, PR interval, P-wave duration, LA 
enlargement, and left ventricular hypertrophy) udvalgt til at skulle indgå i en 
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multivariat model med henblik på at forudsige risikoen for udvikling af POAF. Ved 
at tilføje EKG variablerne til de kliniske variabler blev arealet under en receiver 
operating characteristic (ROC) kurve signifikant øget fra 0.54 to 0.67. Blandt patienter 
med kun en risikofaktor for POAF udviklede blot 20% POAF medens 100% af 
patienterne med fire risikofaktorer udviklede POAF. 
Studie II: I alt 4.766 patienter gennemgik hjertekirurgi af de nævnte typer i 
studieperioden og 2.978 patienter med en gennemsnitsalder på 66,4 år blev inkluderet 
i undersøgelsen. Blandt disse modtog 609 patienter (21%) ≥ 1 erytrocyttransfusion i 
operationsdøgnet. POAF blev diagnosticeret hos 752 patienter (25%) and patienter 
der modtog transfusion var i øget risiko sammenlignet med ikke-transfunderede 
patienter (justeret OR for patients der modtog blod: 1.37; 95% CI: 1.11-1.69, 
p=0.004). Selvom erytrocyttransfusion var associeret med udvikling af POAF var 
blodets lagringstid i blodbanken ikke systematisk associeret med en øget risiko for at 
udvikle POAF. 
Studie III: Èn patient blev ekskluderet fra studiet idet der ikke blev udtaget en 
tilstrækkelig mængde atrievæv til analyse. I alt 22, 14, 10 og tre patienter gennemgik 
henholdsvis isoleret CABG, klapkirurgi, kombinationer heraf eller anden from for 
hjertekirurgi I studieperioden. Gennemsnitsalderen ± SD var 65.98 ±10.40 år. Atten 
patienter (36.7%) udviklede POAF. Hverken koncentrationen af EPA, DPA and DHA 
i atrievæggen eller i plasma kunne forudsige udvikling af POAF. Der var en 
significant korrellation mellem koncentrationerne i plasma og i atrievæv. 
Konklusioner: 
ECG variable identificeret fra rutinemæssige præoperative EKG optagelser kan 
sammen med udvalgte kliniske data være værdifulde ved forsøg på at forudsige hvilke 
patienter, der er i risko for at udvikle POAF efter hjertekirurgi (studie I). Endvidere 
er også transfusion med erytrocytter associeret med en øget risiko for at udvikle 
POAF, men blodets lagringstid i blodbanken har ikke noget særlig betydning (Studie 
II). Koncentrationen af EPA, DPA and DHA i atrievæggen og i plasma fosfolipider 
korrelerer indbyrdes med er ikke korreleret til udviklingen af POAF (Study III). 
Resultaterne fra de individuelle studier inkluderet i denne ph.d. afhandling 
repræsenterer et forsøg på en multidirektionel søgen efter nye potentielle prædiktorer 
associeret med udvikling af POAF efter hjertekirurgi. Specielt resultaterne fra studie 
I kan viser sig værdifulde, hvis de inkluderes i fremtidige modeller der skal bruges til 
at forudsige patienters risiko for at udvikle POAF efter hjertekirurgi. 
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ACRONYMS AND ABBREVIATIONS 
AF: Atrial fibrillation 
ACC: Aortic cross clamp 
ACE: Angiotensin-converting enzyme 
AUC: Areas under the curve 
BMI: Body mass index 
CABG: Coronary artery bypass grafting 
CI: Confidence interval 
COPD: Chronic obstructive pulmonary disease 
CPB: Cardiopulmonary bypass 
DHA: Docosahexaenoic acid 
DPA: Docosapentaenoic acid 
ECG: Electrocardiogram 
EPA: Eicosapentaenoic acid  
FPR: False positive rate 
IABP: Intra-aortic balloon pump 
LAE: Left atrial enlargement 
LVH: Left ventricular hypertrophy 
NOPOAF: No postoperative atrial fibrillation 
n-3 PUFA: n-3 polyunsaturated fatty acids 
POAF: Postoperative atrial fibrillation 
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RBC: Red blood cell 
ROC: Receiver operating characteristic 
TPR: True positive rate 
WDHR: Western Denmark Heart Registry 
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CHAPTER 1. INTRODUCTION  
1.1 Cardiac surgery and postoperative complications  
 
Cardiac surgery is still experiencing developments. Surgery is offered to patients with 
increasing age and an increasing number of comorbidities. In this chapter, I will 
provide a brief review of cardiac surgery in general, including common postoperative 
complications. 
 
After the first successful heart surgery was performed by Dr. Ludwig Rehn of 
Frankfurt, Germany, who repaired a stab wound to the right ventricle on September 
7, 1896, a new age of cardiac surgery started (1). Due to the rapid development of the 
heart-lung machine and anesthesia, cardiac surgery became safe and widely available. 
However, patients undergoing cardiac surgery are still at risk of morbidity and 
mortality. Potential postoperative complications include, e.g., complications related 
to the cardiovascular and respiratory systems, the kidneys and the central nervous 
system such as congestive heart and respiratory failure, myocardial infarction, renal 
failure and thromboembolic complications including stroke (2–4). The use of 
cardiopulmonary bypass equipment also introduces a distinguished set of potential 
postoperative complications involving vasospasm, altered platelet-endothelial cell 
interactions and a generalized inflammatory response initiated by blood contacting 
the synthetic surfaces of the extracorporeal circulation. All these complications play 
a role in relation to postoperative morbidity and mortality following cardiac surgery 
(5,6). 
 
One of the most common complications following cardiac surgery is new-onset 
postoperative atrial fibrillation (7,8). In the rest of this thesis, the abbreviation of 
POAF will refer to new-onset postoperative atrial fibrillation.  
The mechanisms by which POAF develops following cardiac surgery are not fully 
understood, but they seem to be multifactorial (9). Because POAF is associated with 
early and long-term negative outcomes following cardiac surgery (5,10–13), more 
information is needed regarding the predictors and risk factors for POAF to be able to 
direct increased attention toward the prevention of POAF in high-risk patients. 
Multidirectional efforts should be conducted to identify potentially new predictors and 
risk factors for POAF to be able to identify a greater number of high-risk patients. 
This PhD thesis will focus on identifying potentially new risk factors and predictors 
of POAF following cardiac surgery, thus serving as an example of a multidirectional 
approach to this research field in cardiac surgery. 
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The studies included in this thesis may increase the possibility of identifying more 
patients at high risk of POAF following cardiac surgery. Furthermore, an increased 
focus on identifying patients at high risk may contribute to a reduction in 
postoperative morbidity and mortality in cardiac surgery if prophylactic treatment is 
initiated among these patients.  
In the next chapter, I will provide a review of the definition, incidence, 
pathophysiology, risk factors, prognosis and preventive strategies related to POAF. 
 
 
1.2 Postoperative new-onset atrial fibrillation following cardiac 
surgery 
1.2.1 Definition and incidence of POAF 
 Atrial fibrillation (AF) is a cardiac arrhythmia with irregular atrial activity that 
restricts the function of effective atrial contraction and causes a disordered rhythm 
that often occurs rapidly, with or without symptoms (14). Figure 1 shows 
electrocardiogram (ECG) recordings from patients with sinus rhythm and AF, 
respectively.  
Figure 1. Sinus rhythm (above) and atrial fibrillation (below) in the 
electrocardiogram. 
 
 
 
AF is a common adverse outcome following cardiac surgery, and if this arrhythmia 
develops in patients who never experienced this arrhythmia prior to surgery, this 
arrhythmia is called POAF.  
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POAF develops in 10-65% of patients undergoing cardiac surgery, depending on the 
definition, type of surgery and diagnostic criteria (15–18). In a multicenter study, the 
incidence of POAF following coronary artery bypass grafting (CABG) was similar 
among patients in South America (17.4%) and Asia (15.7%), but the incidence was 
higher in the United States (33.7%), Canada (36.6%), Europe (34.0%), the United 
Kingdom (31.6%), and the Middle East (41.6%) (p<0.001) (19). POAF develops most 
frequently between the second and fourth days after cardiac surgery, but it can start at 
any point during the recovery period (20).The development of POAF prolongs the 
hospital stay and is associated with an increased risk of early and late stroke as well 
as mortality (21–23). 
1.2.2 Pathophysiology and risk factors/predictors of POAF 
To date, the precise electrophysiological mechanisms underlying the development of 
POAF remain incompletely understood, and the cause is likely multifactorial. Several 
predictors and risk factors (patient-related, surgical and postoperative factors) have 
been associated with the development of POAF in cardiac surgery. Pre-operative 
patient-related factors that have been identified are, e.g., advanced age, gender, 
pulmonary hypertension, diabetes, body mass index (BMI), left atrial enlargement 
(LAE), left ventricular hypertrophy (LVH), antiarrhythmic drug use, and gene 
expression. Perioperative factors are, e.g., type of surgery, surgical atrial incisions, 
atrial ischemia, pulmonary vein vent, venous cannulation, cardiopulmonary bypass 
time, and aortic cross-clamp time; post-operative factors are, e.g., volume overload, 
oxidative stress, pericardial inflammation, excessive production of catecholamines, 
enhanced sympathetic nervous system activity, and interstitial mobilization of fluid 
after surgery, respiratory compromise, and chronic obstructive pulmonary disease 
(COPD) (17,19,24–34). Figure 2 shows most of the common risk factors/predictors 
for POAF.  
Many of the abovementioned factors are probably triggers and associated with the 
development of POAF due to atrial incisions, the development of atrial ischemia and 
myocardial fibrosis, which might distinguish atrial effective refractory periods and 
slow atrial conduction (17,19,24–34). This phenomenon may explain the increased 
range of the P-wave duration in a signal-averaged electrocardiogram related to the 
increased risk of POAF in cardiac patients in a observational study (31) (Figure 2). 
Furthermore, the surgical procedure itself physically alters the cardiac structure and 
likely creates the electrophysiologic substrate, which may be vulnerable to rhythm 
disturbances and contribute to both abnormal atrial conduction and refractoriness and 
the growing rate of the occurrence of triggering events (17). Occasionally the 
occurrence of AF is accompanied by electrophysiological remodeling and atrial 
structural remodeling. The former appears within a shorter time of the onset of 
arrhythmia in comparison to the latter, which more likely occurs over a longer 
timescale (14). Electrical remodeling in atrial tissue is delayed after depolarization 
and decreases the action potential, depending on the ion channel, which may be prone 
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to AF (14,35). Three electrophysiological models have been proposed that include the 
“multiple-wavelets” hypothesis (36), the single- or multiple-driver model of the 
genesis of AF (37) and the focal activity in the pulmonary veins near the left atrium 
(38). Furthermore, atrial structural remodeling with atrial dilation also supports 
induced AF (39). According to multiple plausible models, the underlying mechanisms 
of POAF development may be multifactorial and not understood completely for 
cardiac surgical patients. The initiation of POAF depends on the presence of an 
electrophysiological substrate that triggers multiple re-entry wavelets resulting from 
the dispersion of atrial refractoriness (40). These risk factors may alter normal atrial 
conduction and refractoriness. It is still attractive to explore the possible mechanism 
linking cardiac surgery and new-onset POAF.  
Figure 2. Risk factors/predictors and potential mechanisms of postoperative atrial 
fibrillation.  
         
 
 
 
 
 
 
 
 
 
 
 
 
Note: AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; POAF: 
postoperative atrial fibrillation. 
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1.2.3 Prognosis of POAF 
For many years, POAF in patients undergoing cardiac surgery was considered to be 
an unimportant, self-limiting arrhythmia that self-resolved to a normal sinus rhythm 
in a short time. Furthermore, POAF does not always lead to discomfort, 
cerebrovascular accident and in-hospital mortality (41). However, several 
postoperative negative outcomes have been associated with POAF. Some research has 
identified an association between POAF and a two- to four-fold increased risk of 
stroke (8,42). In a study among 6,477 patients who underwent isolated first-time 
CABG, the prolonged hospital stay after surgery was 14 days for patients with POAF 
compared with 10 days for patients without POAF (p<0.0001) (8). In another study, 
a similar result was described regarding the length of hospital stay (15.3±28.6 vs. 
9.3±19.6; mean number of days± standard deviation, p=0.001), corresponding to an 
additional cost of more than $10,055 for each patient in hospital stay (43). Other 
negative postoperative outcomes that have been associated with POAF are acute 
kidney injury, perioperative myocardial infarction, cardiac failure, ventricular 
arrhythmias, need of intra-aortic balloon pump use, encephalopathy and infections, 
prolonged ventilation, hypotension, pulmonary edema, and increased need for pacing 
and readmission to the intensive care unit (8,15,41,44–46). Whether there is a cause-
effect relationship between POAF and the outcome mentioned remains to be 
elucidated. 
1.2.4 Preventive strategies for POAF 
As described previously, the incidence of POAF is associated with increased 
morbidity and mortality as well as increased costs after cardiac surgery. Therefore, 
several preventive strategies have been evaluated to prevent development of POAF. 
Some of these strategies will be discussed below. Figure 3 shows commonly used 
strategies for POAF. 
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Figure 3. Preventive strategies for postoperative atrial fibrillation. 
 
 
 
 
 
 
 
 
 
 
 
Note: n-3 PUFA: n-3 polyunsaturated fatty acids; POAF: postoperative atrial fibrillation 
 
The prevention of POAF may involve medical prevention. Medical prevention to 
reduce the risk of POAF includes the use of β-blockers (e.g., metoprolol and sotalol), 
amiodarone, steroids and antioxidant vitamins. The benefit of these therapies in 
relation to POAF after cardiac surgery have been demonstrated in a number of 
previous studies (47–49) (Figure 3). In the 2016 European Society of Cardiology 
(ESC) Guidelines for the management of atrial fibrillation developed in collaboration 
with the European Association for Cardio-Thoracic Surgery (EACTS), perioperative 
oral β-blocker therapy had been recommended for the prevention of POAF after 
cardiac surgery (Class I, Level B) (50). Amiodarone is also recommended as a 
prophylactic therapy to prevent the development of POAF after cardiac surgery (Class 
IIa, Level A) (50). In a randomized, controlled, double-blind trial including 250 
consecutive CABG patients, postoperative prophylaxis with amiodarone reduced the 
risk of POAF. The occurrence of AF after operation in the amiodarone prophylaxis 
group was lower compared with the placebo group (11% versus 26%, p <0.01); 
however, the number of hospital stay days was not significantly different between the 
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two groups (9.0 (95% confidence interval (CI): 8.0–10) vs.9.4 (95% CI: 7.6–11.2), 
p=0.69) (51) (Figure 3).  
Decreased levels of serum electrolytes such as potassium and magnesium may 
increase the risk of POAF in patients after surgery, and perioperative repletion of 
empiric potassium and magnesium therapy in adult cardiac surgical patients may 
decrease the risk of POAF (52,53) (Figure 3).  
 
Some others possibly effective therapies may also prevent the development of POAF, 
including digoxin, antiarrhythmic drugs, calcium channel blockers, angiotensin 
inhibition, statins, N-acetylcysteine, colchicine, fish oil, glucocorticoids, posterior 
pericardiotomy and anterior fat pad preservation (19,34,48,54–60) (Figure 3), but 
these modes of preventions have not been well validated.  
 
Results from studies regarding the benefit of prophylactic epicardial atrial pacing are 
controversial. Some studies have demonstrated a benefit of pacing for the prevention 
of POAF (61–64) (Figure 3), whereas other studies have not (65,66). With regard to 
the atrial pacing strategy, which may include left atrial, right atrial and bilateral atrial 
pacing protocols, controversial results have been obtained (61–66). In a randomized 
study including a total of 132 patients who underwent CABG, the prevalence of POAF 
was significantly decreased in the biatrial pacing group compared with the no pacing 
group (12.5% vs. 41.9%; p<0.05) (62). This result was consistent with previous 
findings (64). However, in two randomized studies with 61 CABG patients and 154 
cardiac surgery patients, respectively, there were no significant differences regarding 
the occurrence of POAF (37% vs. 33%, p>0.7 and 26% vs. 37.5%, p=0.4, 
respectively), or between the right atrial pacing group and the no pacing group (29% 
vs. 33%, p>0.7) as well as left atrial pacing group and no pacing group (20% vs. 
37.5%, p=0.14), respectively (61,65). In a randomized, double-blind cohort study with 
118 cardiac surgery patients, there was a significant reduction in the occurrence of 
POAF among 41 patients with biatrial pacing compared with 38 patients with right 
atrial pacing (10% vs. 32%; p=0.01) (63). Similar results have been described in 
another randomized study among 132 CABG patients (62). Interestingly, a 
randomized study including 100 patients undergoing CABG showed that the 
incidence of POAF was comparable with patients without pacing by postoperative 
day 4 (25.5% vs. 28.6%; p=0.90), even though atrial ectopy significantly differed 
between the two groups (2,106 ± 428 vs. 866 ± 385 per 24 hours, p=0.0001) (66). 
   
The cause of POAF is multifactorial and still not fully understood, and more 
knowledge about risk factors and predictors would facilitate the development of more 
efficient methods to prevent this common postoperative complication. One strategy 
would be to look for potential new risk factors and predictors. 
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1.3 Potential new predictors and risk factors of POAF in cardiac 
surgery 
Efforts to reduce the negative outcomes following POAF should include efforts to 
identify new predictors and risk factors of POAF, thus increasing the possibility of 
identifying more patients with a high risk of POAF for whom prophylactic 
measurements can be taken.  
Many studies have been conducted to elucidate risk factors and predictors related to 
the development of POAF in patients undergoing cardiac surgery. Several predictors 
of POAF are well known, such as age, race, hypertension, BMI, myocardial infarction 
(MI), COPD, prior stroke, low left ventricular ejection fraction (LVEF), and type of 
surgery (23,67–70) (Figure 2). However, more information about potential new 
predictors is needed to identify more patients with a higher risk. 
    1.3.1 ECG markers as predictors for AF and POAF 
POAF does not differ from other types of AF in ECG. Some characteristics of ECG 
have demonstrated great potential for predicting POAF in patients who might be at a 
high risk prior to cardiac surgery in several studies (31,71–75). Steinberg et al. 
enrolled a total of 130 patients undergoing cardiac surgery in a prospective 
observational study, in which 33 patients (25%) developed POAF at 2.6 ± 2.0 (days ± 
SD), and the signal-averaged P-wave duration was significantly (p<0.001) longer in 
the POAF group (71). A case-control study with 105 consecutive patients undergoing 
elective CABG showed that a combination of a P-wave duration >155 ms and serum 
magnesium on the first postoperative day of <0.7 mmol/L had a sensitivity of 75%, a 
specificity of 80% and a positive predictive accuracy of 62% for predicting POAF 
(72). In a large study with more than 280,000 individuals, both short and long P-wave 
durations (76) and PR intervals (77) in the ECG were associated with an increased 
risk of AF during a median follow-up of 6.7 years. In the National Registry to 
Advance Heart Health study of 25,268 patients from 106 centers with left ventricular 
dysfunction, the QRS duration was a strong independent predictor of AF (odds ratio 
(OR): 1.20; 95% CI: 1.14–1.25) (78). In a large ECG study, a J-shaped association 
was found between the heart rate-corrected (QTc) interval duration and the risk of 
AF(79). In another study, POAF was independently related to the presence and 
number of fragmented QRS complexes (fQRS) in patients undergoing CABG surgery. 
In addition, fQRS on pre-op surface ECG had high predictive value for new-onset 
POAF (80). Nevertheless, the predictive ability of all of the studies with their final 
prediction model was moderate. In contrast, in a study with a total of 13,356 patients 
undergoing cardiac surgery, there was no relationship between the P-wave duration, 
PR interval, QRS duration and semi-quantitative ECG diagnosis of atrial enlargement 
and an increased risk of POAF (74). This result is likely due to the complex and 
multifactorial nature of this arrhythmia. The effect of electrophysiological 
measurements aimed at predicting the risk of POAF in routine clinical settings 
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necessitates further investigation. Therefore, more studies of ECG markers from 
routine pre-operative ECGs should be performed that combine, e.g., clinical data with 
ECG findings to enhance the possibility of predicting the risk of POAF following 
cardiac surgery.  
1.3.2 Allogeneic red blood cell transfusion and POAF 
Perioperative blood transfusion in patients undergoing cardiac surgery, whether of 
allogeneic red blood cells (RBC), platelets or plasma, is an important technology, and 
transfusion rates ranging between 30% and 90% are often described (81,82). 
Perioperative allogeneic blood transfusion is associated with the risk of transfusion 
reactions, transmission of infections and increased morbidity and mortality (83). 
Furthermore, RBC transfusion seems to be associated with an increased risk of the 
development of POAF (84,85). A plausible reason for such an association may be the 
relationship between intraoperative blood transfusion and a postoperative systemic 
inflammatory response syndrome (SIRS) (86). In this observational study among 
553,288 patients with a broad spectrum of surgeries (general surgical, vascular, 
thoracic, ear-nose-throat, and orthopedic procedures), RBC transfusion was 
associated an increased risk of SIRS compared with non-transfused patients (p<0.001) 
(86). The concept that inflammation is a causative pathophysiologic factor in relation 
to the development of POAF is sustained by accumulating evidence (87). In several 
studies, a number of inflammatory changes, including raised CRP levels, interleukin-
6, and leukocyte counts, are associated with the development POAF in patients 
undergoing cardiac surgery (88–92). In a study of 5,841 patients undergoing cardiac 
surgery, intensive care unit transfusion was associated with an increased risk of POAF 
(OR per unit transfused: 1.18; 95% CI: 1.14-1.23; p<0.0001). Among 1,360 
propensity-matched patients undergoing cardiac surgery, similar results were 
obtained (85). Another retrospective cohort study in a single center involving 4,028 
patients undergoing cardiac surgery showed that blood transfusion in patients was 
directly related to an increased risk of POAF during the postoperative period in 
comparison to non-transfused patients (27% vs. 20.4%, p<0.001) (93). Furthermore, 
the risk of POAF in CABG patients increased significantly with an increasing number 
of transfused RBC units in two retrospectively studies including 98 and 879 
participants, respectively (both p<0.001) (94,95). However, in a more recent 
prospective randomized trial involving 446 patients undergoing on-pump CABG, 
there was no association between the number of transfused RBC units during surgery 
and the increased risk of POAF (p=0.7) (96). However, the abovementioned studies 
investigating the association between blood transfusions and POAF did not consider 
the age of the transfused blood. A number of studies have focused on whether an 
increased storage time of RBCs in the blood bank prior to transfusion is related to an 
increased risk of adverse outcomes in patients undergoing cardiac surgery. The results 
from these studies are controversial (97–101). Several observational studies have 
shown that storage of RBC for >2 weeks is related to adverse events, e.g., infections, 
renal and respiratory disorders, in-hospital mortality and one-year mortality (97,100). 
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However, other studies have failed to provide results consistent with these findings 
focusing on early or late mortality and multiple organ dysfunction (98,99,101). A 
plausible explanation for adverse outcomes correlated to older blood are the well 
described “storage lesions,” which are structural and functional changes that occur in 
stored RBCs over time (102,103). The storage time of RBCs prior to transfusion may 
play a role as RBCs undergo significant changes during storage, which may 
potentially increase the risk of SIRS and other negative outcomes (104,105) including 
POAF. Indeed, only a few studies have focused on the development of POAF in 
patients undergoing cardiac surgery in relation to the transfusion of “older” versus 
“younger” blood (106), and therefore additional investigations regarding this issue are 
needed.  
1.3.3 Marine n-3 fatty acids in relation to POAF 
Marine long-chain n-3 polyunsaturated fatty acids (n-3 PUFA) are fatty acids with the 
first double bond located at the third carbon atom from the methyl terminus of the 
carbon chain (107). Alpha-linolenic acid (ALA, 18:3w3), eicosapentaenoic acid 
(EPA, 20:5w3), docosapentaenoic acid (DPA, 22:5w3) and docosahexaenoic acid 
(DHA, 22:6w3) are members of the n-3 PUFA family. EPA and DHA are believed to 
have more important biological functions (108,109). Humans must obtain marine n-3 
PUFA from external sources such as seafood. In general, fish oils, with their three 
major n-3 PUFAs ( EPA,DPA and DHA), may have beneficial anti-inflammatory and 
anti-fibrotic as well as direct electrophysiological effects in cardiac myocytes (110–
112). These observed properties of n-3 PUFAs make them attractive potential agents 
to decrease the occurrence of POAF in cardiac surgery patients. Moreover, treatment 
with n-3 PUFAs in animal studies has revealed a significant reduction of the atrial 
effective refractory period and inducibility associated with AF (113). Therefore, 
intake of marine n-3 PUFAs might facilitate the prevention of POAF (59,113). Such 
beneficial effects are supported by results from several randomized studies (113). In 
two recent meta-analyses including 2,687 patients from 8 randomized controlled trials 
and 4,335 patients from 19 randomized controlled trials, respectively, it was 
concluded that n-3 PUFA supplementation reduced the incidence of POAF in patients 
undergoing cardiac surgery (114,115). However, other studies concluded that there 
was no convincing evidence for the reduction of POAF following the use of n-3 
PUFAs (116–122). In a double-blind, randomized, controlled trial involving 194 
subjects undergoing cardiac surgery, all of the participants received either high 
monounsaturated sunflower oil or 4.6 g/day of n-3 PUFAs three weeks before surgery, 
and the incidences of POAF were 48% in the control group (high monounsaturated 
sunflower oil) and 37% in the fish oil group (4.6 g/day of n-3 PUFAs), respectively, 
(OR: 0.70; 95% CI: 0.39-1.28; p=0.25) (123). In another randomized, double-blind, 
multicenter, clinical trial involving 1,516 patients undergoing cardiac surgery, the 
occurrence of POAF was 30.0% in the fish oil group and 30.7% in the control group 
(olive oil) (OR: 0.96; 95% CI: 0.77-1.20; p=0.74) (124). Because of the different 
conclusions, additional studies are needed to evaluate the therapeutic potential of n-3 
PUFAs and the efficacy for the prevention of POAF in patients after cardiac surgery. 
Furthermore, laboratory studies investigating the degree of marine fatty acid 
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incorporation into tissues, including the atrial wall, are needed. To date, no studies 
have investigated the relationship between the content of marine n-3 PUFAs in atrial 
tissue and the risk of POAF after cardiac surgery. 
 
The literature review described above supports a multifactorial cause of POAF. 
Several predictors and risk factors have been associated with development of POAF 
in patients undergoing cardiac surgery, but further multidirectional efforts are needed 
for doctors to be able to identify more patients at an increased risk of developing 
POAF. The results from studies investigating potentially new risk factors and 
predictors of POAF will improve knowledge to facilitate strategies to identify patients 
who may benefit the most from initiatives to prevent the risk of POAF. 
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CHAPTER 2. AIMS AND HYPOTHESES 
The overall aim of this PhD thesis is to serve as an example of a multidirectional 
search for potential new predictors of POAF by performing the three individual 
studies outlined below. 
 
1. The aim of study I was to investigate whether ECG markers from routine 
pre-operative ECGs can be used in combination with clinical data to predict 
new-onset POAF following cardiac surgery using an electronic algorithm 
capable of reading minor ECG changes. We hypothesized that minor 
preoperative ECG markers in combination with clinical data can be 
identified as predictors for development of POAF in cardiac surgery.  
 
 
2. The aim of study II was to evaluate whether RBC transfusion in general and 
the storage time of allogeneic RBCs in the blood bank (i.e., age of transfused 
allogeneic RBCs) is associated with the development of POAF following 
cardiac surgery. We hypothesized that RBC transfusion in general and a 
prolonged storage time of transfused RBC in the blood bank is associated 
with an increased risk of POAF in cardiac surgery. 
 
  
3. The aim of study III was to evaluate whether n-3 PUFA concentrations in the 
atrial tissue and in the blood (plasma phospholipids) could predict the 
development of POAF and whether concentrations in the atrial wall reflected 
concentrations in the blood. We hypothesized that specific compositions of 
n-3 PUFAs in the atrial tissue are associated with a decreased risk of POAF 
and the composition of fatty acids in the atrial tissue reflects fatty acids in 
the blood.      
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CHAPTER 3. METHODOLOGY, 
MATERIALS AND METHODS 
3.1 Study designs 
Different study designs were used in the three studies included in this thesis.  
Study I and II were retrospective studies based on clinical and laboratory data 
available from different existing databases, registers and patient records, while study 
III was a prospective study in which both clinical and laboratory data were collected.  
Study I was a retrospective case-control study, while Study II was a retrospective 
observational cohort study based on prospectively collected data from different 
databases. In contrast, Study III was a prospective observational study combining 
laboratory and clinical data.  
  
3.2 Data from clinical databases and registers       
The studies were based on data collected from the patient records (Study I&III), the 
Western Denmark Heart Registry (WDHR) (Study I, II, III), local databases in the 
blood banks (Study II), and blood and tissue samples (Study III).                                       
As the primary data for Study II in particular were retrieved from existing clinical 
databases and registers, it is important to be aware that the Danish National Health 
Service provides tax-funded medical care for all Danish residents. Due to the unique 
Central Personal Registry number assigned to each Danish citizen at birth and to 
immigrated residents, the linkage between hospital administrative systems and several 
clinical and laboratory databases can be performed at an individual level. 
The Danish Civil Registration System was built in 1968 and contains information 
recorded electronically regarding sex, date of birth and other continuously updated 
information including place of residence, citizenship, emigration, immigration, 
spouse, parents and children, and siblings (125).  
The WDHR is a population-based clinical database containing health care 
information. The WDHR was launched on January 1, 1999, and it contains detailed 
information on all patients with validated data (detailed patient and procedural data) 
(126). The purpose of maintaining the database is to monitor and improve the quality 
of cardiac intervention in the Central and Western Denmark Regions comprising 
approximately three million inhabitants, which is equivalent to 55% of the Danish 
population.  
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Information related to all blood transfusions (RBCs, platelet or plasma) delivered to 
the patients were retrieved from local databases in the blood banks located at Aalborg 
and Aarhus University Hospital (components, number of units, date of delivery and 
storage time in days prior to transfusion). 
 
3.3 Study populations and methods 
In the following sections, materials and methods, including the description of study 
populations, are provided in individual papers. A brief description of the studies is 
given below. 
Study I: 
A total of 100 patients who underwent elective first-time cardiac surgery between 
January 1, 2011 and December 31, 2014, including CABG, aortic or mitral valve 
surgery or a combination of these procedures, were included in the study. Using the 
patient records, we identified 50 patients who developed POAF and 50 control 
patients who did not develop POAF (NOPOAF). No specific matching was 
performed, and the total number of 100 patients was chosen arbitrarily because this 
was a hypothesis-generating study that could not be based on information from 
previous studies. Most of the patients included in the analysis underwent surgery 
consecutively, but a few additional patients were included due to missing data in the 
patient records, thus extending the time period. Patients with a pre-operative history 
of AF, left and right incomplete or complete bundle branch block, and patients with 
permanent pacemakers were excluded.   
POAF was defined as new-onset AF prior to hospital discharge, documented by paper 
ECG and the requirement for medical attention and treatment. Clinical data and 
patient demographics were retrieved from the WDHR or from the patient records they 
were not available in the registry. 
Paper ECGs within a month prior to operation were retrieved from the patient records 
and converted to a digital version for analysis. Five ECG parameters (QRS duration, 
PR interval, P-wave duration, LAE, and LVH correlating with LAE and fibrosis) were 
measured by two independent reviewers (Figure 4) (127), and four multivariate 
models to predict POAF were assessed using logistic regression. They consisted of a 
clinical model (Model C), an ECG model (Model E), a combined clinical/ECG model 
using all nine variables (Model CE-9) and a combined clinical/ECG model using 
univariate pre-specified variables (Model CE-4) (127). 
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Figure 4. ECG interval and amplitude measurements (127). 
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Study II: 
A total of 4,766 consecutive adult patients (>18 years old) who underwent either on 
or off pump CABG, conventional valve and combined surgeries at Aalborg or Aarhus 
University Hospitals between January 1, 2010 to December 31, 2014 were identified 
from the hospital administrative systems and the WDHR (126). The two hospitals 
serve a population of approximately 2.5 million people, corresponding to 
approximately 33% of the total population in Denmark. Patients with a history of atrial 
fibrillation or flutter prior to surgery and patients with an invalid personal registration 
number were excluded. Patients who died or did not receive RBC transfusions on the 
day of surgery were excluded because those who died did not have the opportunity to 
develop POAF and to ensure that a blood transfusion was administered prior to 
development of the primary outcome of interest, i.e., POAF. Information about all 
blood transfusions (RBC, platelet or plasma) delivered to the patients was retrieved 
from local databases in the blood banks (components, number of units, date of 
delivery and storage time in days prior to transfusion). Patients were classified as 
having received either no or an actual number of RBC units. 
POAF was defined as new-onset AF or atrial flutter occurring postoperatively during 
hospitalization regardless of the duration and whether the patient required treatment 
due to POAF. 
Study III: 
A total of 50 patients who underwent first-time elective cardiac surgery were enrolled 
between December 1, 2014 and April 30, 2015 at Aalborg University Hospital, 
Denmark. Twenty-two, 14, 10 and three patients underwent isolated CABG, isolated 
valve surgery, combinations or other cardiac surgery, respectively. The main 
exclusion criteria were a history of any type of preoperative atrial fibrillation or atrial 
flutter, use of a pacemaker and non-elective surgery. Clinical demographic data and 
perioperative data were retrieved from the WDHR and electronic patient records. A 
10-ml blood sample and a right atrial tissue sample were obtained from each patient 
during surgery. Extraction of total lipids from plasma and atrial tissue (128,129) and 
separation of the phospholipid fatty acid fraction (130) were performed by a modified 
version of a previously described method. The fatty acid composition both in plasma 
and atrial tissue were identified and analyzed by gas chromatography and expressed 
as a percentage of the total fatty acid content after methylation. 
Any episode of POAF prior to hospital discharge was documented by paper ECG 
using the same definition applied in study I.  
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3.4 Statistical analysis    
The statistical method varied among the three studies. Baseline and surgery 
characteristics for continuous variables are expressed as the mean ± standard deviation 
(SD), and an absolute number or percentage is reported for categorical variables. Chi-
squared tests for categorical variables and analysis of variance for continuous 
variables were used (Study II). A p<0.05 (two-tailed) was defined as statistically 
significant, and confidence intervals (CIs) were determined at the 95% level. Stata 13 
(StataCorp LP, Tx, USA) (Study I&III) and R version 3.2.2 (Study II) were employed 
to analyze the data. 
    3.4.1 Study I 
The univariate independent t-test and combined multivariate logistic regression were 
performed to assess the association between predictors and POAF. The area under a 
receiver operating characteristic (ROC) curve was used to evaluate the predictive 
abilities of all four prediction models. Cross-validated areas under the curve (AUC) 
were computed by eliminating each patient once from the sample to accommodate for 
over-fitting (131). The Youden index was used to measure the maximized sensitivity 
+ specificity from ROC curves to optimize thresholds of POAF prediction from 
univariate clinical and ECG variables (132). Any clinical or ECG variable value 
exceeding the ROC was considered the optimal threshold and considered a risk factor 
for POAF. Furthermore, in the prediction models, the cut-off value for high risk was 
modified from 0 to 100%, and any patient with a predicted POAF probability who 
exceeded the cut-off value was stratified as high risk.  
    3.4.2 Study II 
The association between RBC transfusion on the day of surgery, RBC storage time 
and dose-dependence for the subpopulation of patients who received RBCs and had a 
risk of developing POAF was evaluated by multiple logistic regression. The OR was 
adjusted by the following potential confounders: patient age, gender, COPD, presence 
of peripheral arteriosclerosis, preoperative treatment with a β-blocker, ACEI and 
calcium antagonists and type of surgery including on and off pump regarding the 
CABG patients. A restricted cubic spline was applied to evaluate the association 
between the specific storage time of the RBCs and the risk of POAF in the transfused 
patients.  
     3.4.3 Study III 
The proportions of marine n-3 PUFAs (EPA, DPA, DHA, EPA+DHA and 
EPA+DPA+DHA) both in plasma and atrial tissue contents were calculated for the 
Pearson product-moment correlation and supplemented with confidence intervals. 
Scatter plots with a regression line and superimposed confidence bands were drawn 
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to display the correlations. Logistic regression was performed to evaluate the 
association between the marine n-3 PUFA levels and the risk of POAF, which was 
adjusted by the following variables (age, CABG and COPD). ORs with 95% CIs were 
reported. The area under the receiver operating characteristics curve was used to 
assess the predictive value from marine n-3 PUFAs for POAF. Cross-validation was 
applied to accommodate for potential overfitting.  
 
3.5 Ethics  considerations 
Study I and II were approved by the Danish Data Protection Agency (record numbers: 
2008-58-0028 and 2014-41-3419). Informed consent was obtained from each patient 
before participation in Study III, which was approved by the Research Ethical 
Committee of the Northern Denmark Region (N-20140070). All three studies were 
conducted in accordance with The Code of Ethics of the Helsinki Declaration. For 
register-based studies, there is no requirement for either ethical approval or informed 
consent from the participants in Denmark. 
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CHAPTER 4. RESULTS 
Detailed results from the individual studies are described in the individual papers. A 
summary is provided below. 
4.1. Study I 
Demographic and operative details of the patients in the two study groups are shown 
on Table 1 (127).   
Table 1. Patient demographics and operative information (127). 
Variables NOPOAF 
(n=50) 
POAF 
(n=50) 
p value 
Age, years 65.5 ± 10.4 69.6 ± 9.6 0.044 
Male, % 66 72 0.666 
Body mass index, kg/m2 27.4 ± 5.3 27.6 ± 4.6 0.825 
Prior myocardial infarction, 
% 
26 28 1.000 
LVEF, % 56.1 ± 9.5 55.3 ± 10.6 0.692 
Logistic EuroSCORE II 4.6 ± 3.0 5.2 ± 2.2 0.271 
Peripheral vascular disease, 
% 
2 2 1.000 
Comorbidities    
Diabetes Mellitus, % 30 22 0.225 
COPD, % 2 12 0.112 
Pre-operative medications    
β-blockers, % 44 44 1.000 
Calcium antagonists, % 22 32 0.368 
ACE inhibitors- 
captopril, % 
30 38 0.527 
Operative data    
CABG, % 58 64 0.666 
Valve surgery, % 34 28 0.208 
Combination, % 8 8 1.000 
CPB time, min 108.8 ± 34.0 104.9 ± 32.3 0.620 
ACC time, min 72.6 ± 32.0 70.7 ± 28.3 0.785 
    
NOTE: Data are presented as the mean ± standard deviation or as a percentage. Abbreviations: 
POAF, postoperative atrial fibrillation; NOPOAF, no postoperative atrial fibrillation; LVEF, 
left ventricular ejection fraction; COPD, Chronic obstructive pulmonary disease; ACE, 
angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CPB, 
cardiopulmonary bypass; ACC, aortic cross clamp; IABP, intra-aortic balloon pump 
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Males made up 72% and 66% of each group consisting of a total of 100 patients. As 
might be expected, age differed significantly (p=0.044) between the groups; the mean 
age ± SD was 69.6 ± 9.6 years and 65.5 ± 10.4 years in the POAF and NOPOAF 
group, respectively. Four ECG variables, including a longer P-wave duration (7 ms, 
p=0.006; 95% CI: 2-12), PR interval (19 ms, p=0.014; 95% CI: 3-21), QRS duration 
(12 ms, p=0.003; 95% CI: 5-20) and signs of LAE (38%, p=0.0001; 95% CI: 21%-
55%) could be used to distinguish between patients who developed and who did not 
develop POAF.  
AUCs with and without cross-validation of the four models (Model C, Model E, 
Model CE-9 and Model CE-4) are shown in Table 2.  
The predictability of the development of POAF in Model E (AUC=0.713; 95% CI: 
0.610-0.815, with cross-validation) was significantly powerful compared with 
Model C (AUC=0.536; 95% CI: 0.421-0.650, with cross-validation) and is shown in 
Figure 5.  
The optimal univariate thresholds (OT) of the ROC curve determined using Youden 
indices for the predictability of the development of POAF from clinical 
characteristics, which include age (>65 years), gender (male), BMI (>25 kg/m2) and 
valve surgery or combined surgery, and ECG characteristics including QRS duration 
(>118 ms), PR interval (>192 ms), LAE and LVH. 
For patients having any combination of one to four of the risk factors in Model CE-4 
exceeding OT, the likelihoods of POAF were 20% (one variable >OT), 50% (two 
variables >OT), 80% (three variables >OT), and 100% (four variables >OT), as shown 
in Fig 6.  
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Table 2. Area under the ROC curve (127).  
 
NOTE: CI, confidence interval; AUC, area under the curve; BMI, body mass index; LAE, left 
atrial enlargement; LVH, left ventricular hypertrophy; dur, duration. 
   
 
 
 
 
 
 
 
 AUC [95% CI] 
Clinical (Model C) 
(Age, gender, BMI, type of surgery) 
   
w/o cross validation  0.671 [0.561 0.781] 
with cross validation 0.536 [0.421 0.650] 
ECG (Model E) 
(PR, P-dur, QRS-dur, LAE, LVH) 
   
w/o cross validation 0.774 [0.682 0.867] 
with cross validation 0.713 [0.610 0.815] 
Clinical & ECG (Model CE-9) 
(Age, gender, BMI, type of surgery,   
PR, P-dur, QRS-dur, LAE, LVH) 
   
w/o cross validation  0.792 [0.705 0.879] 
with cross validation 0.665 [0.557 0.774] 
Clinical & ECG (Model CE-4) 
(Age, PR, QRS-dur, LAE) 
   
w/o cross validation  0.780 [0.696 0.865] 
with cross validation 0.736 [0.643 0.830] 
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Figure 5. ROC curves for the clinical model and the ECG model (127).  
        
NOTE: FPR: false positive rate; TPR: true positive rate.  
   
Figure 6. Proportion of patients with POAF as a function of risk factors in the 
POAF prediction model (127). 
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4.2 Study II  
A total of 4,766 patients underwent cardiac surgery during the study period in the two 
hospitals. We included 2,978 patients with a mean age ± SD of 66.4 ± 10.7 years, 
among whom 752 patients (25%) developed POAF. Patients with POAF were more 
likely to be older (70.0 ± 9.4 vs. 65.2 ± 10.8 years, p<0.0001) and to suffer from 
comorbidities such as diabetes mellitus, COPD and previous stroke in comparison to 
patients without POAF. Furthermore, valve or combined surgery were more common 
among patients who developed POAF. Overall, 609 patients (20.4%) received ≥1 
transfusion of RBC on the day of surgery. Transfused patients were more likely to be 
older compared with non-transfused patients (70.5 ± 10.5 vs. 65.4 ± 10.5 years, 
p<0.0001). The distribution of the maximal and mean storage time of RBC units 
transfused into patients is shown in Figure 7. 
Figure 7. Distribution of the maximum (on top) and mean (below) storage time of 
transfused red blood cells.  
  
Note: Dashed lines represent the average storage time.  
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Transfused patients had a higher risk of developing POAF compared with non-
transfused patients (OR: 1.79; 95% CI: 1.48-2.17; p<0.001; OR: 1.37; 95% CI: 1.11-
1.69; p=0.004, after adjustment). There was a dose-dependent risk for the 
development of POAF in transfused patients receiving 4-6 units of RBCs compared 
with patients receiving 1-3 units of RBCs (OR: 1.62; 95% CI: 1.08-2.42; p=0.019). 
The ORs for developing POAF among patients who were transfused with RBCs stored 
either <14 days or ≥14 days according to the maximal storage time of the RBCs and 
non-transfused patients were 2.01 (95% CI: 1.56-2.59; p<0.001) and 1.59 (95% CI: 
1.23-2.06; p<0.001), and 1.50 (95% CI: 1.15-1.97; p=0.003) and 1.24 (95% CI: 0.94-
1.64; p=0.120), after adjustment, respectively. The same pattern was observed for 
transfused patients divided according to the mean storage time of the transfused 
RBCs. 
The association between the RBC storage time and the risk of developing POAF are 
shown in Figure 8. The baseline risk (dotted line) was computed as the risk when 
receiving 1-3 units of RBC, male gender, age <60 years, receiving no medication (β-
blocker, ACE-inhibitor, calcium antagonist), not having COPD or peripheral 
arteriosclerosis and undergoing a combined surgery type.  
Figure 8. Risk of developing postoperative atrial fibrillation according to the storage 
time of transfused red blood cells. 
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4.3 Study III 
Blood and tissue samples were obtained from 50 patients, but the tissue sample from 
one patient was insufficient for analysis. Therefore, we only included 49 of the 
patients in the analyses. The mean age ± SD of these participants was 66.0 ± 10.4 
years. A total of 22 patients underwent isolated CABG, 14 patients underwent a valve 
procedure, and ten or three patients underwent combined or other cardiac surgery. 
Overall, 18 patients (36.7%) developed POAF. The patients who developed POAF 
tended to be older (68.0 ± 9.3 vs. 64.9 ± 11.0 years), were more commonly females 
and diabetics, and had a longer ECC time (121.2±65.6 vs. 104.5 ± 32.1 minutes), 
aortic cross-clamp time (85.0±47.8 vs. 60.6±32.2 minutes) and postoperative 
ventilation time (35.5±72.8 vs. 13.8±12.7 hours) compared with the patients in the 
NOPOAF group. 
There were no correlations between the development of POAF and the concentrations 
of n-3 PUFAs in atrial tissue and blood, and the concentrations of n-3 PUFAs in the 
atrial wall and blood did not predict the development of POAF. However, significant 
correlations were observed between n-3 PUFAs in tissue and blood. There were 
significant correlations of EPA, DHA, EPA+DHA and total marine n-3 PUFA (but 
not DPA) content between plasma and right atrial wall tissue. 
Thus, the concentrations of n-3 PUFAs in the atrial tissue and plasma phospholipids 
failed to predict the development of POAF. Therefore, we did find significant 
correlations of the EPA (0.72), DHA (0.52), EPA+DHA (0.60) and total marine n-3 
PUFA (0.51) (but not DPA (0.21) composition between plasma phospholipids and 
atrial tissue (Figure 9). There was no association between the concentration of marine 
n-3 PUFAs in atrial tissue and the risk of POAF with or without adjustment (Table 3 
and Figure 10). 
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Figure 9. Correlations of marine n-3 PUFA concentrations in plasma phospholipids 
and in atrial tissue. 
 
Note: PUFA, polyunsaturated fatty acids; EPA, eicosapentaenoic acid; DPA, docosapentaenoic 
acid; DHA, docosahexaenoic acids. 
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Table 3. Association between concentrations of marine n-3 PUFAs in atrial tissue and 
the risk of POAF.  
 
Note: *Adjusted by age, chronic obstructive pulmonary disease and coronary artery bypass 
grafting.  
PUFA, polyunsaturated fatty acids; SD, standard deviation; POAF, postoperative new-onset 
atrial fibrillation; NOPOAF, no postoperative new-onset atrial fibrillation; CI: confidence 
interval; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic 
acids. 
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Figure 10. ROC curves regarding the risk of POAF following cardiac surgery based 
on marine n-3 PUFA concentrations in plasma phospholipids (red line) and atrial 
tissue (blue line). 
 
Note: Adjustments by age, chronic obstructive pulmonary disease and coronary artery bypass 
grafting were performed. 
ROC, receiver operating characteristic; POAF, postoperative new-onset atrial fibrillation; 
PUFA, polyunsaturated fatty acids; AUC, area under the curve; FPR: false positive rate; TPR: 
true positive rate. 
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CHAPTER 5. DISCUSSION 
5.1 General discussion in relation to the literature                                                          
The overall aim of this thesis was to serve as an example of a multidirectional search 
for potential new risk factors and predictors of POAF following cardiac surgery by 
performing the three above-described individual studies. The three studies were 
performed with a focus on a potential association between POAF and preoperative 
ECG diagnostics in combination with clinical patient characteristics, storage time of 
the transfused RBCs, and the n-3 fatty acid composition in the atrial wall, respectively. 
Of these potential predictors of POAF, only ECG diagnostics combined with clinical 
data provided any value for predicting the development of POAF.  
However, no single risk factor or prognostic factor for the development of POAF in 
cardiac surgery is effective alone, and combinations of different risk factors and 
predictors should be included in prediction models in relation to the development of 
this condition. 
In a multicenter risk model with multivariable factors including, e.g., age and type of 
surgery, treatment with medicine to predict the development of POAF in 4,657 
patients undergoing CABG surgery revealed an area under the ROC curve showing 
that the power of the predictive probability of POAF was 0.77 (19). In another 
predictive model with 1,851 CABG patients, only four variables (age, prior history of 
AF, P–wave duration and low cardiac output) were involved, and the area under the 
ROC curve was 0.69 (133). A POAF scoring system was derived and validated by 
Giovanni et al. in a study of 17,262 patients following cardiac surgery and included 
preoperative factors. This system indicated that the incidence of POAF was 42.5% in 
patients with a POAF score ≥3 (134). More recently, a number of studies have 
reported that the CHADS2 and CHA2DS2-VASc scoring systems, which is normally 
used to predict stroke in AF, are useful for predicting the development of POAF in 
patients undergoing cardiac surgery (135–138). However, the prediction of POAF 
using these scoring systems is moderate, and no single predictive model regarding 
POAF following cardiac surgery has ever shown adequate power to be superior to the 
others. Multidirectional studies of risk factors and predictors of POAF in cardiac 
surgery patients are required to enhance these prediction models. 
 
5.2 ECG diagnostics for the prediction of POAF 
Study I indicated that a multivariate ECG model for the prediction of POAF using the 
PR interval, P-duration, QRS-duration, LAE, and LVH should be combined with 
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clinical characteristics such as age, gender, BMI and type of surgery to significantly 
increase the possibility of predicting POAF in patients undergoing cardiac surgery. 
A predominant patient characteristic in our prediction model was patient age, as the 
association between age and POAF has been consistently described in several studies 
(139) and the incidence of POAF has been reported to increase with increasing age 
(19,41,50). In a retrospective cohort study including 6,475 patients who underwent 
CABG, POAF was diagnosed in 994 patients, and an age >65 years was an 
independent predictor for development of POAF (OR: 2.4; 95% CI: 2.06-2.74; 
p<0.0001) (8). In another recent retrospective analysis among 999 patients undergoing 
cardiac surgery, age ≥65 years was also a risk factor for the development of POAF 
(24). In a population-based prospective cohort study among non-surgical patients 
regarding the prevalence, incidence and lifetime risk of AF included 6,432 persons 
with a mean follow-up time of 6.9 years, the AF incidence rate increased from 0.7% 
at the age of 55-59 years to 17.8% among those aged 85 years and above (140). An 
increasing incidence of AF with increasing age was also observed in two other studies, 
including 9511 non-surgical patients (age >50 years) and 5201 non-surgical patients 
(age >65 years), respectively (141,142). In the 2016 ESC Guidelines, opportunistic 
screening using ECG for AF is also recommended among all patients aged >65 years 
(Class I, Level B) (50).  
In previous studies, male gender (142), BMI (143), and type of surgery (19) have been 
shown to be risk factors for POAF in addition to advanced age both in a prospective 
observational study including 5,201 non-surgical patients, among 4,657 cardiac 
surgery patients and in a meta-analysis including 36,147 patients undergoing cardiac 
surgery (19,142,143). This finding is in accordance with the results presented in Study 
I of the present thesis. However, the results reported in the literature are inconsistent. 
In a cohort study of 5,201 non-surgical people aged ≥65 years, the incidences of AF 
per 1000 person years by age were 26.4% for men and 14.1% for women, with or 
without cardiovascular disease (142). However, another recent observational study 
conducted in 144 patients following adult aortic arch repair requiring deep 
hypothermic circulatory arrest evaluated gender in relation to POAF using univariate 
analysis (29). In concordance with Study I in the present thesis, this study did not 
identify gender as a risk factor for POAF (OR: 1.32; 95% CI: 0.68-2.58; p=0.41).  
In a meta-analysis of 18 observational studies with 36,147 patients evaluating whether 
obesity (defined as a BMI > 30 kg/m2) was associated with POAF in patients 
undergoing cardiac operations, obese patients had a modestly higher risk of POAF 
compared with non-obese patients (OR: 1.12; 95% CI: 1.04-1.21; p<0.002) (143). In 
contrast, obesity did not show an increased risk of POAF in another meta-analysis 
including 44,647 patients undergoing cardiac surgery (144). In study I of the present 
thesis, we initially attempted to include BMI in our Clinical Model, but it was 
excluded in the final prediction model. The above meta-analyses supported our 
opinion that BMI was not a major risk factor for POAF.  
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In one of the meta-analyses mentioned above (143), the association between obesity 
and POAF did not vary significantly according to the type of cardiac surgery. In 
contrast, in a large multicenter prospective observational cohort study of 4,657 
patients undergoing cardiac surgery in 17 countries, 32.3% of the patients developed 
POAF, and patients who underwent valve surgery were at a higher risk of POAF (OR: 
1.74; 95% CI: 1.31-2.32; p<0.001) (19). In Study I, we did not find any significant 
association between POAF and BMI and the type of surgery. These contradictory 
results may be explained by differences, e.g., in patient cohorts, surgical and 
anesthesiological techniques, local diet, genetics and the relatively small number of 
patients included in our study. 
In model E of Study I, four ECG parameters (P-wave duration, PR intervals, QRS 
duration and signs of LAE) showed significant differences between the two groups, 
but not LVH. For Model CE-4, the P-wave duration was included in the definition of 
LAE. The significance of the three variables in model E and the one variable in model 
C was therefore selected for the final model called Model CE-4. Several previous 
studies have shown a strong correlation between the LA size and the risk of new onset 
AF (142,145). In the Framingham Heart Study (145), M-mode echocardiography was 
routinely performed in 1,924 subjects aged >59 years. This study showed that for 
every five mm increase in LA diameter, the risk of AF increased by 39% (p=0.001). 
In the Cardiovascular Health Study consisting of 5,201 adults aged ≥65 years (142), 
the risk of new onset AF was more than four times higher in patients with a LA 
diameter exceeding 50 mm (assessed by echocardiography) compared with <30 mm. 
 
In another study of 265 patients with isolated mitral valve disease, aortic valve disease 
or asymmetric septal hypertrophy, AF was rare when the LA diameter was <40 mm 
but common when the diameter was >40 mm (146). A prospective study with a total 
of 205 patients undergoing cardiac surgery showed that the left atrial volume (LAV) 
measured by transthoracic echo was significantly larger in patients with AF and was 
a strong independent predictor of the occurrence of POAF, with a 26% increased risk 
of AF for every 10 ml/m2 increase in LAV (147).  
 
The study also showed that patients with LAV >32 ml/m2 had an almost five-fold 
incremental risk of POAF, even after adjusting for age and clinical risk factors. The 
LA dimension and volume assessed by echocardiography have also been used in 
different research as strong predictors of POAF combined with other risk factors in 
patients who had undergone cardiac surgery (24,74,148).  
 
In a recent two-dimensional speckle tracking echocardiography study of 48 
consecutive CABG patients, the left atrial volume index (LAVI) and fibrosis were 
significantly higher in patients who developed POAF, and a LAVI >36 ml/m2 
predicted POAF with a sensitivity of 84.6% and a specificity of 68.6% (149).  
 
The prediction of AF based on ECG parameters has been carried out in several studies 
(71,72,74–78,80,150–152). We found that the combination of the P-terminal force on 
the ECG and P-wave duration in lead II were significantly associated with POAF, in 
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accordance with previous findings (74,76,151). The Framingham Heart Study (151), 
with 1,550 participants aged ≥60 years, showed that the upper 5% of the P-wave 
maximum duration had a HR of 2.19 (95% CI: 1.46-3.30; p<0.001) and a HR of 2.51 
(95% CI: 1.13-5.57; p=0.024) in a gender- and age-adjusted analysis and a 
multivariable-adjusted analysis for AF, respectively. In the Copenhagen ECG Study 
(76), the long P-wave duration also showed a strong association with an increased risk 
of AF. A study conducted in 13,356 cardiac surgery patients revealed a more negative 
deflection of the P-wave in V1, even after adjustment associated with an increased 
risk of POAF (74). This result can likely be explained by a delayed depolarization 
wave front in LAE through the enlarged LA wall, resulting in a delay of the terminal 
portion of the P-wave and thus extending the P-wave duration. Furthermore, LA could 
also rotate the P-wave vector to the left in ECG, causing a negative terminal 
component of the P-wave in lead V1. 
 
Prolongation of the electrocardiographic PR interval and QRS duration was shown to 
be associated with POAF in Study I. These findings are supported by various studies 
in cardiac surgery and in other conditions (73–75,77,78,80,152–154). An association 
between an electrocardiographic PR interval and incident AF was observed in the 
Framingham Heart Study and was included as a risk score for AF (154). A PR interval 
above the 95th percentile (≥196 ms for women, ≥ 204 ms for men) has also been shown 
to be associated with AF when evaluated using a multivariable-adjusted hazard ratio 
(HR) (77). There was an 18% increased risk in women and an 30% increased risk in 
men in this large population during an average follow-up of 5.7 years in the 
Copenhagen ECG Study (77). This is also in accordance with a recent prospective 
cohort study of a total of 1,227 CABG patients, in which a significantly longer PR 
interval was found in 377 (31%) of the POAF cohort (152).  
In another study of cardiac surgical patients, the OR for POAF was 1.01 using a 
univariate analysis of the PR interval (75). This study showed that the inclusion of 
different ECG variables in a prediction model with only clinical predictors 
significantly improved the area under the ROC from 0.71 to 0.78 (p<0.01). 
Myocardial fibrosis, changes in sympathetic and parasympathetic tone, medications, 
ischemia, and degenerative conduction diseases may all alter the PR interval, which 
is the period reflecting the time required for conduction from the atrial myocardium 
surrounding the sinus node through the AV node to the Purkinje fibers 
(42,51,155,156).  
In a multicenter ADVANCET study of 25,268 patients with LVEF <40%, the OR for 
AF was 1.20 if the QRS duration was prolonged after adjusting for potential AF risk 
factors. The QRS duration was independently associated with AF (78). In another 
study, a prolonged QRS time (p=0.004) was also significantly related to POAF in 
patients undergoing isolated CABG (80). In a study investigating patients with 
cardiomyopathy, the QRS complex duration correlated with the extent of ventricular 
fibrosis (153), and the characteristics of the QRS complex duration in these 
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participants was also probably related to a generalized myocardial fibrosis including 
atrial fibrosis, which may function as a substrate for POAF.  
The results obtained for Study I may, in part, be explained by local fibrosis in dilated 
atria because these pathological changes may alter the normal atrial electrical 
refractoriness and conduction (157–159). Such abnormalities may be detected by 
routine ECG due to the change in P-wave morphology and conduction (75,160,161), 
PR-interval (77) and QRS-duration (78) in patients, providing the substrate for POAF. 
 
5.3 “Fresh” vs. “old” blood transfusion in cardiac surgery  
Study II showed that transfused patients were older and had an increased risk for the 
development of POAF compared with non-transfused patients with or without 
adjustment. An increased risk of POAF showed a dose-dependent relationship in 
transfused patients receiving 4-6 units of RBCs compared with those receiving 1-3 
units of RBCs in Study II. However, there was no association between the RBC 
storage time and risk of POAF in patients receiving RBCs who had undergone cardiac 
surgery. Other observational studies (85,94,95), but not all (96), also found a dose-
dependent association between RBC transfusion and the risk of POAF. In a 
retrospective study of 5,841 on-pump open heart surgery patients and 451 off-pump 
CABG patients, the risk of POAF increased with an increasing number of transfused 
RBC units in ICU patients following isolated off-pump and on-pump CABG (OR: 
1.22; 95% CI: 1.05-1.41; p=0.0075; OR: 1.25; 95% CI: 1.16-1.34; p<0.0001; 
respectively) (85). Interestingly, in the same study, a reduced risk of POAF was 
observed when on-pump cardiac surgery populations received RBCs in the operating 
room (OR: 0.954; 95% CI: 0.912-0.998; p=0.039) (85). This finding is difficult to 
explain. In another study including only 98 patients undergoing on or off-pump 
CABG surgery, the patients who developed POAF received more units of transfused 
RBCs compared with those who did not develop POAF( 9.29 ± 3.34 vs. 6.00 ± 2.15, 
p<0.001) (94). RBC transfusion was associated with an increased risk of POAF 
compared with non-transfused patients (OR: 1.586; 95% CI: 1.252-2.008; p<0.001) 
(94). However, the authors did not evaluate the relationship between the storage time 
of transfused RBCs and POAF.  
A more recent observational study with a total of 879 CABG patients showed that the 
risk of POAF increased with the amount of transfused RBCs. Using logistic regression 
analysis, patients receiving 1-3 units, 4-6 units and 7+ units of RBCs had an OR of 
1.35 (95% CI: 0.89-2.07), 2.28 (95% CI: 1.35-3.87) and 2.21 (95% CI: 1.14-4.28) for 
the risk of POAF, respectively. However, there was no linear relationship between the 
number of transfused RBC units and POAF (95). In contrast, there was no statistical 
association between the development of POAF and intraoperative as well as total RBC 
unit transfusions among 446 patients undergoing on-pump CABG in terms of the risk 
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of POAF (p=0.7, p=0.2, respectively) (96). Regarding intraoperative transfusions, this 
result is consistent with those presented in Study II. 
The development of storage techniques for RBCs has led to increased storage times 
and better quality of the stored RBCs. During storage, RBCs and their supernatant 
undergo progressive structural and functional changes that result in biochemical and 
biomechanical alternations, including cellular membrane changes, reductions of 2,3-
diphosphoglycerate and adenosine triphosphate, and accumulations of bioactive 
substances in the RBC storage medium, leading to a diminished RBC deformability, 
decreased oxygen delivery, increased immunologic activation or suppression and the 
release of proinflammatory cytokines (162,163). These “storage lesions”, which 
cannot be avoided completely, may reduce RBC function and viability and initiate an 
inflammatory response (164) in the recipient, potentially leading to adverse clinical 
events in patients receiving “older” RBCs. In study II, we divided transfused patients 
arbitrarily into two groups according to the storage time of a single transfused RBC 
unit (RBCs stored for either <14 days or ≥14 days), or to either the mean and 
maximum storage age of transfused blood if patients received >1 unit of RBCs. This 
strategy was based on the knowledge that “storage lesions” reflect the deterioration of 
RBCs by biochemical and morphologic changes that most commonly begin to occur 
following two weeks of storage in the blood bank (165). These storage lesions have 
been associated with several postoperative complications, including increased 
mortality. In a large retrospective cohort study among 1,813 trauma patients, RBCs 
stored for more than two weeks appeared to be related to an increase in mortality 
among the patients (166). In another study of 6,002 cardiac surgical patients, patients 
who were transfused with RBCs that had been stored >2 weeks had a higher risk of 
postoperative complications compared with those who were transfused with RBCs 
stored <2 weeks (97). Both short-term and long-term survival were significantly 
decreased (97). These investigations implied that the shelf life time of stored RBCs is 
approximately 2 weeks. Several studies have also divided transfused blood into 
“fresh” or “old” blood” using a cut-off of approximately 14 days (167). 
Only very few studies have investigated the association between the storage time of 
transfused RBCs and the development of POAF (106). In an observational study of 
819 isolated CABG patients, POAF developed significantly more often in transfused 
patients who received blood units stored for >14 days compared with those who 
received blood units stored for <14 days (OR: 1.67; 95% CI: 1.19-2.34; p=0.007) 
(106). However, in Study II, we found no association between an increased storage 
time of allogeneic RBCs and development of POAF in transfused patients following 
cardiac surgery. These distinct findings may be explained by, e.g., differences in 
patient cohorts, different definitions of POAF and different methods for obtaining the 
diagnosis. 
The storage time of RBCs in relation to postoperative outcomes has been investigated 
in other studies focusing on mortality and morbidity other than POAF (101,168,169). 
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In a single-center study of 1,153 adult patients undergoing cardiac surgery, there were 
no significant differences between patients who received RBCs stored for ≤14 days 
compared with those who received RBCs stored for >14 days, regarding the 
development of postoperative renal failure, or infectious or pulmonary complications 
(168). Another retrospective cohort study including 2,715 patients undergoing CABG, 
valve or combined cardiac surgery showed no association between the 1-year survival 
of patients who had received “old” RBCs and “young” RBCs (hazard ratios: 0.97; 
95% CI: 0.69-1.35; p=0.98). However, the risk of 1-year survival significantly 
decreased with an increased number of transfused RBC units (169). In a recent multi-
center randomized, controlled study including 9,285 cardiovascular surgical patients, 
there was no significant difference in in-hospital mortality (12.3% and 11.2%, 
respectively; OR: 1.13; 95% CI: 0.99–1.29; p=0.08) between the short-term storage 
group (mean storage time=13.0 days) and the long-term storage group (mean storage 
time=23.6 days) (101). In contrast, in a retrospective study of 819 consecutive isolated 
CABG patients, the authors found that patients who were transfused with > 14 days 
old RBC units had a significantly higher risk of POAF compared with patients who 
were transfused with < 14-day-old RBC units ( OR: 1.67; 95% CI: 1.19-2.34; 
p=0.007) (106).  
Theoretically, storage lesions in transfused blood may be a possible causal 
explanation for the development of POAF due to the inflammatory response initiated 
by the transfused blood (86). Thus, storage lesions in transfused blood might be an 
explanation for the positive correlation shown by some researchers between RBC 
transfusion and an increased risk of POAF. However, contradictory results from 
different studies may relate to differences in patient populations, different study 
designs, residual confounding and differences regarding the type of blood stored in 
the blood bank, i.e., leukocyte reduced or non-leucocyte reduced RBC units. 
Prospective randomized trials are required to confirm the relationship between the 
storage effects of transfused RBCs and the development of POAF in cardiac surgery 
patients. 
In our study, the mean storage time of transfused RBC was approximately 11 days, 
and the patients who were transfused with more than one unit of RBCs would 
potentially receive a combination of “fresh” and “old” blood if a cut-off value of a 
storage time of < 14 days was used to define “fresh” blood. Therefore, interpretations 
of associations between outcomes and the age of the transfused blood may be very 
difficult. 
There was inadequate evidence in Study II to conclude that the storage time of 
transfused allogeneic RBCs was associated with the development of POAF in patients 
undergoing cardiac surgery, but the association between RBC transfusion and an 
increased risk of POAF has been confirmed in most studies (85,93,95). As allogeneic 
RBC transfusions are associated with increased mortality and morbidity, inclusion of 
the risk of POAF multimodal efforts to decrease rates of allogeneic blood transfusion 
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in patients undergoing cardiac surgery are still important and continuously carried out 
in many centers (170). 
 
5.4 Marine n-3 fatty acids and POAF in cardiac surgery 
Study III demonstrated that there was no association between the concentrations of 
marine n-3 PUFAs (EPA, DPA, DHA, EPA+DHA and EPA+DPA+DHA), both in 
plasma phospholipids and atrial tissue, and the risk of developing of POAF following 
cardiac surgery. Another finding in Study III was the significant correlations between 
the content of EPA (r=0.72), DHA (r=0.52), EPA+DHA (r=0.60) and 
EPA+DPA+DHA (r=0.51), but not DPA(r=0.21), between the atrium and in plasma 
phospholipids.  
We did not find that the content of marine n-3 PUFAs, EPA, DPA and DHA in atrial 
tissue or in plasma phospholipids could forecast an enhanced risk of POAF in patients 
undergoing cardiac surgery. Our study therefore lends no support to an effect of n-3 
PUFAs in relation to prevention of the development of POAF. This finding is 
supported by a randomized, double-blind, placebo-controlled clinical trial including 
108 patients undergoing on-pump CABG. This study did not show any beneficial 
effect of n-3 PUFAs on the occurrence of POAF either in univariate or in multivariate 
Cox regression models, even though levels of EPA and DHA in serum and atrial tissue 
increased in response to n-3 PUFAs over a short-term therapy duration (171). In 
another randomized, double-blinded, placebo-controlled study with 200 patients 
undergoing valve and CABG surgery, the incidence of POAF in the fish oil group 
(intake 4.6 g/day of n-3 PUFAs, 3 weeks prior to surgery) was not statistically 
significant compared with a control group with or without adjustment (OR: 0.70; 95% 
CI: 0.39 -1.28; p=0.25; and OR: 0.63; 95% CI: 0.35-1.11; p=0.11; respectively) (123). 
More recently, n-3 PUFA reduction of inflammatory and oxidative stress was 
confirmed in patients undergoing on-pump cardiac surgery, but the risk of POAF was 
not diminished in patients treated with n-3 PUFAs (2 g⁄day, one week prior to surgery) 
plus vitamin C (1 g⁄day, two days prior to surgery) and E (400 IU⁄day, two days prior 
to surgery) until discharge compared with the placebo group (RR: 0.32; 95% CI: 0.72–
2.71; p=0.325) (172). In a meta-analysis including 11 randomized controlled trials 
with 3,137 patients undergoing cardiac surgery, oral n-3 PUFAs alone (average of 2 
g⁄day) before or after surgery were not effective for the prevention of POAF, whereas 
combination treatment with n-3 PUFAs and vitamins C and E provided beneficial 
results (173). Some other studies have provided consistent results (119,122). The 
results from Study III did not support the association of n-3 PUFAs with the risk of 
POAF. However, interest in n-3 PUFAs has grown in recent years, and their intake, 
which leads to their incorporation into plasma and cardiac myocytes, is believed to 
have anti-inflammatory, anti-oxidative, antifibrotic and antiarrhythmic effects 
(110,112,174,175). An antiarrhythmic effect is supported by several studies that 
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reported significant decreases in POAF with n-3 PUFA supplementation (115). N-3 
PUFAs have been shown to prevent the occurrence of POAF in isolated CABG 
patients who experienced a MI within 3 months (176). A randomized controlled trial 
combining data (n=355) from Australia and Iceland indicated that there may be a U-
shape relationship between DHA levels in RBCs and POAF (121). In a meta-analysis 
including eight randomized controlled studies with 2,687 patients who underwent 
open cardiac surgery, n-3 PUFAs reduced the incidence of POAF both in a fixed-
effects model (OR: 0.84; 95% CI: 0.71-0.99; p=0.04) and a random-effects model 
(OR: 0.75; 95% CI: 0.57-1.00; p=0.05), in particular in patients undergoing isolated 
CABG (OR: 0.66; 95% CI: 0.50-0.87; p=0.003) (59). More recently, another two 
meta-analyses reported identical results, and moreover, n-3 PUFAs decreased the 
hospital stay (114,115). The mechanisms underlying the potential antiarrhythmic 
effect of n-3 PUFAs remain unclear. One potential mechanism may be that n-3 PUFAs 
in cardiac membrane phospholipids increase the membrane fluidity (177) and thereby 
shift the state of cytokines (178), further altering the threshold level for the induction 
of arrhythmia (179), reducing the beating rate and inhibiting the inward sodium 
current and L-type inward calcium current, which inhibits the induction of 
tachyarrhythmia (180). Other potential mechanisms may be responsible for the role 
of n-3 PUFAs in preventing AF, such as a beneficial effect on ion channel 
conductance through incorporation into cardiac membrane phospholipids (181). We 
failed to show any correlation between n-3 PUFA concentrations in the atrial wall and 
blood and the risk of POAF, which indicated that the concentrations in the atrial wall 
were not directly related to the risk of POAF development. 
Further studies with a larger number of patients undergoing cardiac surgery are 
warranted to further examine the role of n-3 PUFA concentrations in the atrial tissue, 
including the effects of a seafood diet as well as of oral and intravenous administration 
of n-PUFAs on these concentrations. 
Although there were no associations between the levels of marine n-3 PUFAs in atrial 
tissue or plasma phospholipids and the risk of POAF development in the patients in 
study III, there were significant correlations between the content of total marine n-3 
PUFAs in the atrium and in plasma phospholipids. In a previous study of 61 on-pump 
CABG patients, samples from both the right atrial appendages and blood were 
collected during surgery. Correlations between the content of marine n-3 PUFAs in 
the atrium and in plasma were identified in accordance with the results from study III 
(182). In a randomized study including a total of 84 subjects undergoing cardiac 
surgery, the EPA and DHA contents in erythrocytes and in myocardial phospholipids 
were correlated in humans (183), providing results that were very similar to ours. This 
observation might also suggest that the fatty acid composition of atrial tissue can be 
readily changed because plasma phospholipids reflect the last few weeks of dietary 
fatty acid intake. However, we cannot exclude the possibility that the diets of the 
participants were constant on a long-term basis. The content of plasma marine n-3 
PUFAs in plasma phospholipids were significantly associated with the atrial tissue 
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levels, indicating that plasma, which is much easier to obtain than atrial tissue - might 
be a useful surrogate marker for the n-3 PUFA status in atrial tissues in humans.                         
  
In the following chapter, I will discuss the strengths and limitations in relation to the 
three studies included in this thesis. 
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CHAPTER 6. STRENGTHS AND 
LIMITATIONS  
The studies included in this thesis have several important limitations. Study I and II 
were limited by their retrospective nature, which can only detect associations in 
contrast to causality between the outcome of interest and the exposures. A multivariate 
logistic regression was applied to minimize confounding due to well-known 
predictors of POAF in all three studies. However, residual confounding may also 
exist. A relatively small cohort size was included in Study I and III, increasing the 
risk of type II error and the single-institution data limit generalizability. The findings 
from these hypothesis-generating studies should therefore preferably be evaluated in 
prospective studies that include a larger number of patients. 
 
Only patients who develop POAF during the hospital stay in the primary cardiac 
center are registered in the WDHR, and thus there is a risk that we did not register all 
POAF cases for each patient. POAF may occur after discharge from the hospital, 
which may result in misclassification regarding the outcome in all three studies and 
weaken the predictive model of POAF development in Study I. However, we have no 
reason to believe that any potential misclassification was related indications of RBC 
transfusion or intake of n-3 PUFAs prior to surgery. Another weakness of the studies 
is that we did not continuously monitor ECGs during the total stay of the patients in 
the hospital after surgery, and thus we might have missed clinically silent episodes of 
POAF. Again, we have no reason to believe that our POAF monitoring differed within 
transfused and non-transfused patients or according to n-3 PUFA intake.  
 
An inflammatory response may be one of several potential mechanisms whereby RBC 
transfusion contributes to POAF (86). We did not collect information about levels of 
inflammatory markers such as IL-6, TNF-α and CRP in our dataset. These markers of 
inflammation have all been related to the development of POAF in previous studies 
(184–186), and missing information for these markers may considered a limitation in 
studies examining risk factors for POAF. 
 
It is a strength of Study II that we included a relatively large number of consecutive 
patients from two university hospitals, which was rather homogenous and used a 
validated database. 
 
One of the strengths of Study III is that we obtained tissue from atrial appendages, 
giving us the opportunity to examine atrial tissue levels of total and individual marine 
n-3 PUFAs and their relationship to POAF, which theoretically may develop in the 
atrial wall and/or in tissue closely related to the atrial wall.  
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CHAPTER 7. MAIN CONCLUSIONS 
The studies included in this dissertation represent an example of a multimodal 
approach to contribute new knowledge regarding the prediction of POAF in patients 
undergoing cardiac surgery. The positive results from study I in particular may 
improve future clinical decision-making regarding prophylactic treatment to prevent 
POAF development following cardiac surgery. 
The main findings in the individual studies included in this thesis are described below. 
 
Study I: ECG markers obtained from a routine preoperative ECG may be helpful in 
predicting new-onset POAF in patients undergoing cardiac surgery, especially if 
combined with specific clinical data. 
 
Study II: In contrast to allogeneic RBC transfusion in general, an increased storage 
time of RBCs is not associated with the development of POAF in cardiac surgery. 
 
Study III: Levels of marine n-3 PUFAs in the atrial wall are not associated with the 
risk of POAF following cardiac surgery, despite significant correlations of marine n-
3 PUFAs in the atrium and in plasma phospholipids. 
 
There are still many unanswered questions regarding the possibility of predicting 
POAF in patients undergoing cardiac surgery.  
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CHAPTER 8. CLINICAL IMPLICATIONS 
AND FUTURE RESEARCH 
New-onset POAF in patients undergoing cardiac surgery is common, and the cause of 
POAF seems to be multifactorial. Numerous risk factors and predictors of POAF have 
been identified and used to guide decision-making regarding prophylactic 
measurements to avoid POAF in patients undergoing cardiac surgery. However, we 
are still not able to identify all patients at risk, and risk models must be improved due 
to the lack of convincing tools.  
Results from this PhD study indicate that accurate prediction models may be 
developed based on various perioperative ECG characteristics and clinical data. The 
result from Study I should be evaluated in larger patient cohorts potentially with 
echocardiographic variables related to electrical conduction abnormalities, which may 
be associated with the development of POAF. Clinical data including dietary habits, 
such as biomarkers related to the intake of marine fatty acids, may also be included in 
future prediction models. 
Future studies should focus on acquiring a better understanding of the mechanisms 
underlying the development of POAF. 
POAF is associated with increased morbidity and mortality that develops several years 
following discharge (8,187). However, it is hard to explain a cause-effect relationship 
between POAF for a few hours in the hospital and an ischemic stroke that occurs 
several years later, unless POAF is just a marker of an increased risk of stroke several 
years after surgery potentially due to the development of AF later in life. Future 
research should be directed towards assessing whether the prevention of POAF in the 
early postoperative period decreases the risk of a future stroke. Furthermore, it would 
be interesting to determine whether predictive models for POAF in the early 
postoperative period would also be able to predict the risk of AF and stroke later in 
life among patients who have undergone cardiac surgery several years prior to these 
situations.  
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